Figure 6From: Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinibPaclitaxel-induced activation of EGFR is blocked by adding neutralizing TGFα antibody. The dose of paclitaxel is 2-fold IC50. The dose of TGFα antibody is 0.15 μg/mL A.PC-9 B. H1650Back to article page